SAN FRANCISCO, April 05, 2016 -- BioQ Pharma, a specialty pharmaceutical company focused on the development and commercialization of large volume ready-to-use infusible pharmaceuticals, announced today that the Company will be presenting at the 15th Annual Needham Healthcare Conference to be held in New York City on April 12th and 13th, 2016.
Josh Kriesel, President and Chief Executive Officer, is scheduled to present on Wednesday, April 13th at 8:40 a.m. Eastern Daylight Time.
About BioQ Pharma
BioQ Pharma is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, Lee's Pharm, Lunatus, and West Pharmaceutical Services.
Company Contact Information: Josh Kriesel President and CEO 415-336-6496 Ron Pauli Chief Financial Officer 415-889-7707 Media: Stephanie Carrington Integrated Corporate Relations, Inc (ICR) 646-277-1282


Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 



